Samuel Waxman Cancer Research Foundation
2019-2021 Cancer Research Awards

REQUEST FOR APPLICATIONS (RFA)

The Samuel Waxman Cancer Research Foundation is pleased to announce a Request for Applications (RFA) for 8 (eight) new two-year awards of $100,000/year. We anticipate funding half of the awards for research that will focus on the interplay of aging and cancer; the other half for research that will address aspects of aberrant gene expression, differentiation, or epigenetic therapies that relate to cancer. Directors of major aging and cancer research programs are invited to submit one application per institution.

Potential themes related to aging and cancer include:

- Aging-associated changes in stem cell function related to cancer
- Mechanisms of age-associated clonal evolution in somatic tissues
- Chromatin/epigenetic mechanisms in aging and cancer
- Mutation and/or de-repression of non-coding genome in aging and cancer
- Aging-associated DNA damage response pathways and genomic instability in cancer
- Aging-associated changes in metabolism related to cancer
- Decline in tissue maintenance in old age as a potential link to cancer incidence
- Contributions of the microenvironment in aging-associated tumor formation
- Inter-organ system communication in aging and cancer
- Human premature aging disorders as model systems of aging-associated cancer
- Novel mouse models to study the role of aging in cancer

Based on its long-standing interest in differentiation therapy for cancer, the SWCRF will continue to solicit applications related to:

- Transcription-based approaches to cancer
- Novel therapies/pathways to overcome defective differentiation of cancer cells
- Targeting aberrant signaling pathways characteristic of the malignant phenotype
- Selective apoptotic agents and pathways in cancer

Recipients of the SWCRF cancer research awards are encouraged to develop collaborations with other SWCRF investigators to continue scientific interactions beyond the term of their grant and form a society of investigators committed to:

Collaboration:

- Formulation of research plans to augment other SWCRF research programs
- Sharing of research materials, reagents, and/or core resources
- Joint publications
- Development of NIH program project grants (P01s) and/or collaborative R01s
Communication:
Interactions at the annual SWCRF Scientific Review Meeting
Subgroup meetings at other meetings such as ASH and AACR

2019 RFA Guidelines
Each center may nominate one Principal Investigator to apply for a two-year grant for up to $200,000 ($100,000 per year, which may include up to 10% for overhead).

Timeline:

- Submit a structured letter of intent (LOI) using the template below: April 1, 2019
- Invitations for Full Application: April 22, 2019
- Full application: June 1, 2019
- Funding decision: July 1, 2019

Funding decisions will be made by peer review, SWCRF Scientific Advisory Board, SWCRF Founder and CEO, Chief Scientific Officer and Chief Mission Officer. Reporting results and the budget process will be discussed at the time of the announcement of the awards.

Submit all inquiries and responses to Ms. Lyris Skinner - lyris.skinner@mssm.edu and Mr. Jesse Dean - jdean@waxmancancer.org.

About the SWCRF

The Samuel Waxman Cancer Research Foundation (SWCRF), founded in 1975, is a non-profit organization dedicated to conducting basic, translational, and clinical research with the goal of developing effective targeted treatments for cancer. SWCRF funds research in leading institutions in the United States, Canada, China, and Israel; fosters collaborations; trains scientists; and organizes international conferences to develop novel approaches to prevent and treat cancer. SWCRF develops research programs in the form of an “Institution Without Walls™” that spans institutions and disciplines and seeks to identify investigators who are best able to attack specific problems related to cancer. To date, the SWCRF has awarded approximately $100 million to more than 200 investigators.

Samuel Waxman, MD
Founder & CEO
SWCRF

Johnathan D. Licht, MD
Chief Scientific Officer
SWCRF

Alan Rosmarin, MD
Chief Mission Officer
SWCRF

William T. Sullivan
Executive Director
SWCRF

Letter of Intent
Title:

PI name, Institution:

Background:

Premise:

Key preliminary data:

Hypothesis:

Specific Aims:

Novelty:

Impact: